April 5, 2012
Shionogi & Co. on April 2 announced it has obtained positive initial results of the PIII SPRING-2 study for integrase inhibitor S/GSK1349572 (dolutegravir), which is positioned as a next global strategic product, for treatment-naïve adults with HIV-1. This is the...read more